熱門資訊> 正文
Zevra股价在FDA关于阿尼莫的会议前上涨16%
2024-08-01 02:49
- Shares of Zevra (NASDAQ:ZVRA) climbed 16% Wednesday ahead of an FDA advisory committee meeting on Friday that will discuss the company’s resubmitted market application for arimoclomol.
- The Danish company is seeking to have the product approved for the treatment of adults and pediatric patients two years of age or older with Niemann-Pick disease type C.
- Zevra (ZVRA) resubmitted the application in December 2023. The FDA declined to approve the product in June 2021, issuing a Complete Response Letter to the product’s former owner, Orphazyme. Zevra (ZVRA) acquired arimoclomol in May 2022.
- The FDA is expected to issue a decision on whether to approve the therapy by Sept. 21.
- Zevra (ZVRA) was formerly known as KemPharm.
More on Zevra Therapeutics
- Zevra Therapeutics, Inc. (ZVRA) Q1 2024 Earnings Call Transcript
- Zevra Therapeutics rises as director buys $60K in company shares
- Zevra announces FDA meeting to review its Niemann-Pick disease type C treatment drug
- Seeking Alpha’s Quant Rating on Zevra Therapeutics
- Historical earnings data for Zevra Therapeutics
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
